Oakley completes sale of investment in Inspired
08 April 2020
Oakley Capital Investments Limited
Oakley completes sale of remaining investment in Inspired
· Proceeds: OCI's share of net proceeds is approximately £99 million
· NAV increase: The sale results in a NAV uplift of 10 pence per share
Oakley Capital Investments Limited1(the "Company" or "OCI"), announces that it has completed the sale of its remaining stake in Inspired. OCI had invested in Inspired through its holding in Oakley Capital Private Equity II ("Fund II")2 and also held a direct stake in the business.
As part of the transaction, both Fund II and OCI have sold down their stakes in full, following partial realisations in 2019 and 2017. OCI's share of net proceeds, from both its direct and indirect stakes, is £99 million (EUR:GBP 1.13), adding approximately 10 pence to the NAV per share compared to the December 2019 position. On a combined basis, the net proceeds represent a 25% uplift to the 31 December carrying value. Following the receipt of proceeds, OCI will have cash of approximately £250 million. This represents approximately 128 pence per share and 36% of NAV as at 31 December 2019.
- ends -
For further information please contact:
Oakley Capital Limited
+44 20 7766 6900
Steven Tredget, Investor Relations
Greenbrook Communications Limited
+44 20 7952 2000
Alex Jones / Gina Bell / James Williams
Liberum Capital Limited (Financial Adviser & Broker)
+44 20 3100 2000
Gillian Martin / Owen Matthews
This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014.
LEI Number: 213800KW6MZUK12CQ815
1 About Oakley Capital Investments Limited ("OCI")
OCI is a Specialist Fund Segment ("SFS") traded investment vehicle, which provides access to the Oakley Funds2. It is a liquid vehicle that aims to provide capital growth and dividends to investors.
2 The Oakley Funds
Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III and Oakley Capital IV, are unlisted mid-market private equity funds with the aim of providing investors with significant long-term capital appreciation. The investment strategy of the funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.
The Investment Adviser
Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.
Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules. The London Stock Exchange has not examined or approved the contents of the Prospectus.
The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Kallelse till extra bolagsstämma i NanoCap Group AB
Aktieägare som vill delta i stämman ska dels vara upptagen i utskrift av aktieboken avseende förhållandena den 24 oktober 2023, dels anmäla sig till bolaget senast den 27 oktober 2023 skriftligen till Box 5141, 102 43 Stockholm eller via e-post till [email protected]. Anm...
Bioextrax: Capacity to accommodate rising interest
American start-up company exercises option for the next periodWarrants subscription adds SEK 10.6 million before issue costsOur model implies a fair valuation of SEK 10.5 per shareBioextrax shows continued progress in its Q2 report for 2023. The company signed a license agreement with the US start-u...